RecruitingNot ApplicableNCT05314400

Gadoxetate Abbreviated MRI in Metastatic Colorectal Cancer

A Prospective Study Evaluating Diagnostic Accuracy, Outcome, and Economic Impact of Abbreviated Gadoxetate-enhanced MRI of the Liver in Patients With Metastatic Colorectal Carcinoma


Sponsor

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Enrollment

200 participants

Start Date

Jul 1, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

After a patient is diagnosed with colon cancer, they receive a CT of the chest, abdomen, and pelvis to see if the cancer has spread (metastasized) to other parts of the body. A common site for the cancer to spread to is the liver. If an abnormality is seen in the liver on CT, sometimes an MRI of the liver is required to determine a) whether it is cancer or not and b) whether there are small tumours in the liver that were not visible on CT. During the MRI, the patient is injected with intravenous (IV) contrast. This makes liver lesions more conspicuous and also helps determine if they are cancerous or not. The most commonly used IV contrast agent is called Gadovist. However, there is another IV contrast agent called Primovist that is better at detecting liver metastases from colon cancer than Gadovist. This is very important information for surgeons, because if they considering cutting out (resecting) the liver tumours, they want to make sure they get them all. Unfortunately, Primovist is used sparingly in Canadian hospitals because it is more expensive than Gadovist and the MRI takes longer. Some early small studies have suggested that it may be possible to shorten the Primovist MRI significantly (e.g. from 60 minutes to 15 minutes), making it economically feasible to offer Primovist to more patients. However, there have not been any large studies performed to confirm these findings. The purpose of this study is to compare the accuracy of colon cancer liver metastasis detection between a regular, full-length Primovist MRI versus a shortened Primovist MRI protocol. The economic impact will also be assessed.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study evaluates whether a shorter, faster version of a liver MRI scan (called abbreviated MRI) using a special contrast dye (gadoxetate) can accurately detect liver metastases in people with colorectal cancer — potentially offering a quicker alternative to a full MRI. **You may be eligible if...** - You are 18 or older with a biopsy-confirmed diagnosis of colorectal cancer - Prior imaging has shown possible liver lesions that may be metastases - You are able to tolerate an MRI scan and have signed informed consent **You may NOT be eligible if...** - You have a metallic implant or medical device that is not MRI-compatible - Your kidney function is severely reduced (eGFR below 30) - You have severe claustrophobia that oral anti-anxiety medication cannot help - You have had a severe allergic reaction to gadolinium-based contrast agents before - You weigh more than the MRI table allows - You are pregnant - Your liver metastases are so widespread they are clearly unresectable - You have severe liver dysfunction (ALBI grade 3) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTFull Gadoxetate-enhanced liver MRI

Standard pulse sequences

DIAGNOSTIC_TESTShortened Gadoxetate-enhanced liver MRI

Fewer pulse sequences


Locations(2)

St. Joseph's Healthcare

London, Ontario, Canada

London Health Sciences Centre

London, Ontario, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05314400


Related Trials